GLP-1 receptor agonist tied to similar thyroid cancer risk as DPP-IV, SGLT2 inhibitors
Adults who initiate a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those prescribed a DPP-IV inhibitor or an SGLT2 inhibitor, according to study findings published in The BMJ. “GLP-1 receptor agonist use was not associated with a substantially increased risk of thyroid cancer over a mean follow-up of 3.9 years,” Björn Pasternak, MD, PhD, associate